Scientific Advances in Antiviral Strategies for Flu Treatment
Influenza, caused by the influenza virus, remains a significant global health challenge, largely due to the virus's ability to continuously evolve. Despite the availability of vaccines and antiviral medications, effectively managing influenza requires a comprehensive understanding of the virus's characteristics, life cycle, and treatment options. This article explores recent advances in antiviral strategies for treating influenza, focusing on medications and treatment for both influenza A and B strains.
Influenza Virus Characteristics
Influenza is an Orthomyxoviridae type virus, and it's primarily a respiratory infection. Flu viruses are divided into A, B, and C Influenza A and B viruses are the culprits for most human seasonal flu cases. Influenza A viruses are also further divided into subtypes based on two surface proteins, hemagglutinin (HA) and neuraminidase (NA). The most common human subtypes are H1N1 and H3N2. Influenza B viruses are less recurrent than A and there are two primary lineages Victoria and Yamagata.
Influenza is one of the most difficult viruses to eradicate because it's very quickly mutating. This mutation process could result in antigenic drift (small alteration to surface proteins of the virus) or antigenic shift (large alteration), making long-term effective treatments and vaccines harder to come by. Since influenza A in particular is so mutated, it can bring about pandemics and we have to keep changing vaccines and antiviral therapies.
Influenza Virus Life Cycle
Understanding the life cycle of the influenza virus is essential to the development of effective antiviral strategies. The life cycle of an influenza virus consists of several key steps: viral adsorption, entry into host cells, uncoating, RNA replication, packaging and budding, and viral release. In terms of antiviral therapy, a variety of drugs have been developed for different stages of the influenza virus life cycle.
Adsorption and entry: Influenza viruses bind to sialic acid residues on the surface of host cells through hemagglutinin on their surface, thereby achieving adsorption and entry into host cells. This stage is an important target for antiviral drugs, such as natural small molecules such as quercetin that can inhibit the adsorption and entry of the virus.
Uncoating and RNA replication: After the virus enters the host cell, viral ribonucleic acid proteins (vRNPs) are released from the viral envelope and transported to the nucleus via nuclear localization sequences. Within the nucleus, viral RNA-dependent RNA polymerases initiate transcription and replication of viral RNA.
Packaging and budding: Newly synthesized viral RNA binds to the nucleoprotein and polymerase complex to form new vRNPs, which are subsequently transported to the cell membrane for assembly and budding.
Viral release: The viral release phase relies primarily on the action of neuraminidase, which enables the virus to be released from the host cell surface and infect other cells by cleaving sialic acid residues on the surface of the virus and host cells. Neuraminidase inhibitors (such as oseltamivir and zanamivir) are currently commonly used anti-influenza drugs that prevent viral release by blocking NA activity.
Fig.1 The life cycle of influenza virus. (Nuwarda, Rina Fajri, et al., 2021)
Causative Agent of Influenza Virus
The causative agents of influenza are RNA viruses, primarily of the influenza A and B types, which belong to the Orthomyxoviridae family. The influenza A virus is particularly noteworthy due to its ability to undergo antigenic shift, a phenomenon that allows the virus to change its surface proteins dramatically, leading to new subtypes that can evade the immune system and cause widespread outbreaks. Influenza B, while less prone to major antigenic shifts, still poses significant challenges, especially in populations at high risk for complications, such as the elderly and immunocompromised individuals.
Both influenza A and B viruses are highly contagious and can result in severe symptoms, ranging from fever and body aches to respiratory distress, especially in high-risk individuals.
Influenza Virus Antiviral Development
In recent years, significant progress has been made in the development of antiviral medications to combat influenza, addressing challenges such as the virus's high mutation rate and emerging drug resistance. Key scientific advancements in this area include:
Development of Novel Antiviral Drugs: The need for new antiviral treatments has intensified due to the increasing concerns of resistance and the rapid mutation of the influenza virus. New antiviral drugs, such as baloxavir marboxil and laninamivir octanoate, inhibit viral replication and spread, providing promising alternatives for treatment. Additionally, drug design strategies based on structure, mechanism, and multivalent binding are being employed to address resistance issues and accelerate drug development.
Classification and Application of Antiviral Drugs: Anti-influenza virus drugs are mainly divided into several categories, including hemagglutinin inhibitors, M2 ion channel blockers, viral RNA polymerase inhibitors and neuraminidase inhibitors. For example, oseltamivir (Tamiflu) and peramivir (Rapivab) are widely used neuraminidase inhibitors, while newer drugs like mabaleravir target specific stages in the viral life cycle, offering additional treatment options.
Table.1 Influenza virus related products at BOC Sciences.
| Product Name | CAS Number | Price |
| Influenza-virus-IN-1 | 108729-21-1 | Inquiry |
| Influenza virus-IN-8 | 1627115-50-7 | Inquiry |
| Influenza-virus-IN-4 | 2133818-85-4 | Inquiry |
| Influenza-virus-IN-2 | 2411584-06-8 | Inquiry |
| Influenza-virus-IN-3 | 2412451-16-0 | Inquiry |
| Influenza-virus-IN-5 | 2581825-57-0 | Inquiry |
| Influenza virus-IN-7 | 2703046-92-6 | Inquiry |
| Influenza virus-IN-6 | 2919303-26-5 | Inquiry |
| Oseltamivir | 196618-13-0 | Inquiry |
| Zanamivir | 139110-80-8 | Inquiry |
| Baloxavir marboxil | 1985606-14-1 | Inquiry |
| Laninamivir octanoate | 203120-46-1 | Inquiry |
| peramivir (Rapivab) | 330600-85-6 | Inquiry |
| nitazoxanide (NTZ) | 55981-09-4 | Inquiry |
Influenza A Virus Treatment
Recent advances in antiviral strategies for treating influenza A have been focused on novel antiviral drugs, immune modulation, and addressing drug resistance. The key developments include:
New Antiviral Drugs: Several novel antiviral agents are entering clinical trials, targeting specific stages of the influenza virus lifecycle. These drugs inhibit critical viral proteins such as hemagglutinin, the M2 ion channel, and RNA polymerase, thereby blocking viral replication and transmission. Furthermore, research into computer-aided drug design has led to the discovery of small molecule inhibitors that specifically target the influenza A virus.
Broad-Spectrum Antibodies: A promising approach involves the discovery of broad-spectrum antibodies. For instance, the FI6 antibody has been shown to neutralize all influenza A subtypes, offering a potential solution for universal influenza vaccines. This "super antibody" could provide protection against multiple strains of the virus for years to come.
Innovations in Vaccine Development: mRNA-based universal flu vaccines are being developed, although technical challenges remain. This type of vaccine holds the potential to protect against a broader range of influenza strains through multivalent mRNA vaccines or optimized antigen combinations.
Addressing Drug Resistance: Drug resistance is a major concern, particularly with neuraminidase inhibitors such as oseltamivir and zanamivir. Efforts are underway to identify new antiviral agents that can effectively combat influenza A strains resistant to current therapies.
Immune Modulation Strategies: Beyond direct antiviral treatments, new research has proposed immune modulation strategies, such as monoclonal antibodies targeting M2 ion channel proteins, to enhance the host's immune response and improve antiviral defense.
Combination Therapies and Delivery Innovations: Researchers are exploring the use of combination therapies, which integrate existing antiviral medications with other therapeutic agents. This approach, along with advancements in drug delivery systems, aims to improve treatment efficacy and patient outcomes.
Influenza B Virus Treatment
Treatment for influenza B has also seen significant progress, particularly in the areas of antibody therapies and the development of new antiviral drugs. Key developments include:
Breakthroughs in Antibody Therapies: Antibody treatments targeting the hemagglutinin protein of the influenza B virus have shown great promise. For instance, broad neutralizing antibodies (bnAbs) such as C12G6 and CR8033 can bind to the receptor-binding site (RBS) of the virus, preventing its entry into host cells. C12G6 has been particularly effective in cross-neutralizing multiple influenza B strains, offering strong protective effects in animal models. Other bnAbs, including IgM and IgG classes, have also demonstrated potent neutralizing activity against Influenza B.
Development of New Antiviral Drugs: In addition to traditional neuraminidase inhibitors, researchers are investigating other antiviral compounds for Influenza B. DAS-181, an inhalable dry powder with broad-spectrum antiviral properties, is currently undergoing phase II clinical trials. Other promising compounds, including nitazoxanide (NTZ) and FA-600, have shown antiviral activity against Influenza B. Atractyloside A (AA), a natural compound, also demonstrates potential therapeutic effects against the virus.
Vaccine Development Challenges and Progress: While quadrivalent flu vaccines reduce the incidence of Influenza B infections to some extent, their efficacy in certain populations remains limited. Research efforts are focused on developing more effective vaccines that can better address the evolving and mutating nature of the Influenza B virus.
Drug Resistance Issues: Influenza B viruses have shown resistance to certain antiviral drugs, particularly neuraminidase inhibitors. This necessitates ongoing research and surveillance to monitor resistance patterns. Combination therapies, which can reduce the likelihood of resistance by targeting multiple viral functions, are being explored as an effective strategy.
Summary
Advances in antiviral strategies for treating influenza have significantly enhanced our ability to manage both influenza A and B infections. Neuraminidase inhibitors and RNA polymerase inhibitors continue to be key treatment options, while research into novel therapies targeting various stages of the viral life cycle is ongoing. With the development of broad-spectrum antibodies, immune modulation strategies, and more effective vaccines, the fight against influenza is steadily improving, offering hope for better control of seasonal flu and future pandemics.
References
- Chakraborty, Sambuddha, and Ashwini Chauhan. Fighting the flu: a brief review on anti-influenza agents. Biotechnology and Genetic Engineering Reviews 40.2 (2024): 858-909.
- Nuwarda, Rina Fajri, et al., An overview of influenza viruses and vaccines. Vaccines 9.9 (2021): 1032.
※ Please kindly note that our services are for research use only.